TY - JOUR
T1 - Baseline characteristics, treatment patterns, and outcomes in patients with HER2-positive metastatic breast cancer by hormone receptor status from systhers
AU - Cobleigh, Melody
AU - Yardley, Denise A.
AU - Brufsky, Adam M.
AU - Rugo, Hope S.
AU - Swain, Sandra M.
AU - Kaufman, Peter A.
AU - Tripathy, Debu
AU - Hurvitz, Sara A.
AU - O'Shaughnessy, Joyce
AU - Mason, Ginny
AU - Antao, Vincent
AU - Li, Haocheng
AU - Chu, Laura
AU - Jahanzeb, Mohammad
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research Inc.. All rights reserved.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - Purpose: We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs). Experimental Design: SystHERs (NCT01615068) was an observational, prospective registry study of U.S.-based patients with newly diagnosed HER2-positive MBC. Endpoints included treatment patterns and clinical outcomes. Results: Of 977 eligible patients (enrolled from 2012 to 2016), 70.1% (n ¼ 685) had HR-positive and 29.9% (n ¼ 292) had HR-negative disease. Overall, 59.1% (405/685) of patients with HR-positive disease received any first-line endocrine therapy (with or without HER2-targeted therapy or chemotherapy); 34.9% (239/ 685) received HER2-targeted therapy þ chemotherapy þ sequential endocrine therapy. Patients with HR-positive versus HR-negative disease had longer median overall survival (OS; 53.0 vs 43.4 months; hazard ratio, 0.70; 95% confidence interval, 0.56-0.87). Compared with patients with high HR-positive staining (10%-100%, n ¼ 550), those with low HR-positive staining (1%-9%, n ¼ 60) received endocrine therapy less commonly (64.2% vs 33.3%) and had shorter median OS (53.8 vs 40.1 months). Similar median OS (43.4 vs 40.1 months) was observed in patients with HR-negative versus low HR-positive tumors (1%-9%). Conclusions: Despite evidence that first-line HER2-targeted therapy, chemotherapy, and sequential endocrine therapy improves survival in patients with HR-positive, HER2-positive disease, only 34.9% of patients in this real-world setting received such treatment. Patients with low tumor HR positivity (1%-9%) had lower endocrine therapy use and worse survival than those with high tumor HR positivity (10%-100%).
AB - Purpose: We report treatments and outcomes in a contemporary patient population with HER2-positive metastatic breast cancer (MBC) by hormone receptor (HR) status from the Systemic Therapies for HER2-positive Metastatic Breast Cancer Study (SystHERs). Experimental Design: SystHERs (NCT01615068) was an observational, prospective registry study of U.S.-based patients with newly diagnosed HER2-positive MBC. Endpoints included treatment patterns and clinical outcomes. Results: Of 977 eligible patients (enrolled from 2012 to 2016), 70.1% (n ¼ 685) had HR-positive and 29.9% (n ¼ 292) had HR-negative disease. Overall, 59.1% (405/685) of patients with HR-positive disease received any first-line endocrine therapy (with or without HER2-targeted therapy or chemotherapy); 34.9% (239/ 685) received HER2-targeted therapy þ chemotherapy þ sequential endocrine therapy. Patients with HR-positive versus HR-negative disease had longer median overall survival (OS; 53.0 vs 43.4 months; hazard ratio, 0.70; 95% confidence interval, 0.56-0.87). Compared with patients with high HR-positive staining (10%-100%, n ¼ 550), those with low HR-positive staining (1%-9%, n ¼ 60) received endocrine therapy less commonly (64.2% vs 33.3%) and had shorter median OS (53.8 vs 40.1 months). Similar median OS (43.4 vs 40.1 months) was observed in patients with HR-negative versus low HR-positive tumors (1%-9%). Conclusions: Despite evidence that first-line HER2-targeted therapy, chemotherapy, and sequential endocrine therapy improves survival in patients with HR-positive, HER2-positive disease, only 34.9% of patients in this real-world setting received such treatment. Patients with low tumor HR positivity (1%-9%) had lower endocrine therapy use and worse survival than those with high tumor HR positivity (10%-100%).
UR - http://www.scopus.com/inward/record.url?scp=85081131441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081131441&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-19-2350
DO - 10.1158/1078-0432.CCR-19-2350
M3 - Article
C2 - 31772121
AN - SCOPUS:85081131441
SN - 1078-0432
VL - 26
SP - 1105
EP - 1113
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 5
ER -